Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation.

Scope of the Report:
This report focuses on the Opioid-Induced Constipation in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis. Some of the common symptoms of opioid-induced constipation are hard and dry stools, painful defecation, bloating, distention and bulged abdomen, feeling lethargic, and loss of appetite.
The worldwide market for Opioid-Induced Constipation is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.

Market Segment by Manufacturers, this report covers
AstraZeneca
Takeda Pharmaceutical
Valeant Pharmaceuticals International
Abbott
Bayer
Boehringer Ingelheim
C.B. Fleet
Cosmo Pharmaceuticals
Daewoong
Daiichi Sankyo
GlaxoSmithKline
Ironwood Pharmaceuticals
Johnson & Johnson
Merck
Mundipharma
Nektar Therapeutics
Pfizer
Progenics Pharmaceuticals
Shionogi
SLA Pharma
Sucampo
Synergy Pharmaceuticals
Theravance

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Solid
Liquid

Market Segment by Applications, can be divided into
Drugstore
Hospital
Others

There are 15 Chapters to deeply display the global Opioid-Induced Constipation market.
Chapter 1, to describe Opioid-Induced Constipation Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Opioid-Induced Constipation, with sales, revenue, and price of Opioid-Induced Constipation, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Opioid-Induced Constipation, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Opioid-Induced Constipation market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Opioid-Induced Constipation sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source